Windtree Therapeutics, Inc. Other financial activities

Other financial activities of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Other financial activities growth rates and interactive chart.


Highlights and Quick Summary

  • Other financial activities for the quarter ending December 30, 2019 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Other financial activities decreased by -100.0%
  • Annual Other financial activities for 2019 was $-151 Thousand (a -2.58% decrease from previous year)
  • Annual Other financial activities for 2018 was $-155 Thousand (a -89.41% decrease from previous year)
  • Annual Other financial activities for 2017 was $-1.46 Million (a -306.49% decrease from previous year)
  • Twelve month Other financial activities ending December 30, 2019 was $-151 Thousand (a -50.65% decrease compared to previous quarter)
  • Twelve month trailing Other financial activities decreased by -94.62% year-over-year
Trailing Other financial activities for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$-151 Thousand $-306 Thousand $-2.81 Million $-2.81 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Other financial activities of Windtree Therapeutics, Inc.

Most recent Other financial activitiesof WINT including historical data for past 10 years.

Interactive Chart of Other financial activities of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Other financial activities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.0 $0.0 $0.0 $-0.15 $-0.15
2018 $-0.16 $-0.16
2017 $-2.5 $0.0 $0.05 $0.99 $-1.46
2016 $0.24 $0.4 $0.07 $0.71
2013 $-0.45 $-0.45

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.